2024/06/17 by Bogdan Dume, Emilia Licărete, Manuela Banciu · 1 voice
Biochemistry, Genetics and Molecular Biology · #Advanced biosensing and bioanalysis techniques #CRISPR and Genetic Engineering #RNA Interference and Gene Delivery
paper · pdf · doi:10.1016/j.omtn.2024.102256
openalex publication_date 2024/06/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Although recent advancements in cancer immunology have resulted in the approval of numerous immunotherapies, minimal progress has been observed in addressing hard-to-treat cancers. In this context, therapeutic oligonucleotides, including interfering RNAs, antisense oligonucleotides, aptamers, and DNAzymes, have gained a central role in cancer therapeutic approaches due to their capacity to regulate gene expression and protein function with reduced toxicity compared with conventional chemotherapeutics. Nevertheless, systemic administration of naked oligonucleotides faces many extra- and intracellular challenges that can be overcome by using effective delivery systems. Thus, viral and non-viral carriers can improve oligonucleotide stability and intracellular uptake, enhance tumor accumulation, and increase the probability of endosomal escape while minimizing other adverse effects. Therefore, gaining more insight into fundamental mechanisms of actions of various oligonucleotides and the challenges posed by naked oligonucleotide administration, this article provides a comprehensive review of the recent progress on oligonucleotide delivery systems and an overview of completed and ongoing cancer clinical trials that can shape future oncological treatments.